FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma
- 6 November 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 140 (1), 89-98
- https://doi.org/10.1007/s00432-013-1545-7
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- KRAS Mutation: Should We Test for It, and Does It Matter?Journal of Clinical Oncology, 2013
- Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancerNuclear Medicine Communications, 2012
- PET/CT in the Staging of the Non-Small-Cell Lung CancerJournal of Biomedicine and Biotechnology, 2012
- Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer: A Bivariate Systematic Review and Meta-AnalysisJournal of Thoracic Oncology, 2011
- Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerThe Oncologist, 2011
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?Journal of Clinical Oncology, 2010
- Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC)European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004